Research map: Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes

Back to the article

Papers in this map

  1. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome · Laurence Fardet · 2014 · 1506 citations · Cited by this paper
  2. Issues and Events · 2026 · Related
  3. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025 · Nuha A. ElSayed · 2024 · 1318 citations · Cited by this paper
  4. Reactive Hypoglycemia as a Transient Metabolic Phenotype of Stage 1 and 2 Type 1 Diabetes · 2026 · Related
  5. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes · Kevan C. Herold · 2019 · 1182 citations · Cited by this paper
  6. IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies · 2026 · Related
  7. Trisomy 21 consistently activates the interferon response · Kelly D. Sullivan · 2016 · 397 citations · Cited by this paper
  8. National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000–2022 · 2026 · Related
  9. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions · Massimo De Paschale · 2012 · 336 citations · Cited by this paper
  10. Data-Driven Subclassification of Prediabetes and Diabetes in South Asian Adults From India · 2026 · Related
  11. Treatment of E pstein B arr virus‐induced haemophagocytic lymphohistiocytosis with rituximab‐containing chemo‐immunotherapeutic regimens · Deepak Chellapandian · 2013 · 253 citations · Cited by this paper
  12. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant · 2026 · Related
  13. Routine Epstein-Barr Virus Diagnostics from the Laboratory Perspective: Still Challenging after 35 Years · Ralf D. Hess · 2004 · 233 citations · Cited by this paper
  14. Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor–Induced Diabetes With Seroconversion of GAD Antibodies · 2026 · Related
  15. Epstein–Barr Virus and Hemophagocytic Lymphohistiocytosis · Rebecca A. Marsh · 2018 · 182 citations · Cited by this paper
  16. Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank · 2026 · Related
  17. Immune Dysregulation in Children With Down Syndrome · Dean Huggard · 2020 · 151 citations · Cited by this paper
  18. What Makes the Difference? Predicting Glycemic Trajectories Following Initiation of Automated Insulin Delivery Systems in Youth With Type 1 Diabetes · 2026 · Related
  19. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function · Kevan C. Herold · 2023 · 134 citations · Cited by this paper
  20. Study of Metformin and GLP-1 Receptor Agonist Use in Hidradenitis Suppurativa Using the NIH All of Us Research Program · 2026 · Related
  21. Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome · Xiao‐Fei Kong · 2020 · 91 citations · Cited by this paper
  22. Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes · A. Lledó · 2024 · 51 citations · Cited by this paper
  23. Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab · Chantal Mathieu · 2025 · 16 citations · Cited by this paper
  24. Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes · Kagan Ege Karakus · 2026 · 8 citations · Cited by this paper
  25. Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes · A. Lledó · 2025 · 7 citations · Cited by this paper
  26. Untitled · Cited by this paper

Source: OpenAlex (CC0)